Despite extensive research, there is an unmet need for developing disease-modifying therapies for Parkinson's disease (PD). Failure of certain landmark clinical trials has highlighted the need for a better understanding of the disease pathogenesis as well as identifying the hurdles in developing drug candidates and designing clinical trials. While adhering to these needs, several promising trials are currently underway with the hope of developing reliable targets.
View Article and Find Full Text PDF